Aisner Joseph
University of Medicine and Dentistry of New Jersey , Robert Wood Johnson Medical School, New Brunswick, NJ 08903-2681, USA.
Am J Health Syst Pharm. 2007 May 1;64(9 Suppl 5):S4-7. doi: 10.2146/ajhp070035.
Several new oral chemotherapeutic agents have recently been introduced. Many possess novel mechanisms of action and specific targets that result in different adverse effect profiles from those associated with traditional chemotherapies and hormonal therapies. The potential advantages and challenges associated with oral chemotherapy are discussed.
Use of the oral route is convenient and allows administration to take place at home or in non-traditional settings. However, nausea, difficulty swallowing, patient nonadherence, interactions with drugs and food, other pharmacokinetic factors, and the high cost of treatment can present problems in using these agents by the oral route. Awareness by clinicians of the potential problems with oral chemotherapy can help to avoid or minimize problems that might affect patient outcomes.
While bioavailability studies are often an integral part of developing oral agents, their comparisons with parenteral forms are less well documented. However, studies comparing intravenous 5-fluorouracil (5-FU) with oral 5-FU prodrugs have demonstrated that efficacy, safety, and quality of life are not compromised by the use of oral therapy. Finally, these studies, as well as others, reveal patients prefer the oral route of administration.
近期引入了几种新型口服化疗药物。许多药物具有新颖的作用机制和特定靶点,导致其不良反应谱与传统化疗和激素疗法不同。本文讨论了口服化疗相关的潜在优势和挑战。
口服给药途径方便,可在家中或非传统环境中进行。然而,恶心、吞咽困难、患者依从性差、与药物和食物的相互作用、其他药代动力学因素以及治疗成本高,可能会给口服使用这些药物带来问题。临床医生了解口服化疗的潜在问题有助于避免或最小化可能影响患者治疗结果的问题。
虽然生物利用度研究通常是开发口服制剂不可或缺的一部分,但与注射剂型的比较记录较少。然而,比较静脉注射5-氟尿嘧啶(5-FU)与口服5-FU前体药物的研究表明,口服治疗不会影响疗效、安全性和生活质量。最后,这些研究以及其他研究表明患者更喜欢口服给药途径。